非小细胞肺癌抗血管生成治疗研究现状

doi:10.11904/j.issn.1002-3070.2017.05.017

Abstract

Abstract: Angiogenesis is the physiological process of generating new blood vessels from existing networks.In the tumor microenvironment,the dynamic balance of a growing tumor facilitates the transition to persistent angiogenesis.Antiangiogenic drugs have been used in a variety of solid tumors,including lung cancers,by resisting tumor angiogenesis and inhibiting tumor growth,since human recognized its ability.In this paper,recent research status of tumor angiogenesis and non-small cell lung cancer anti-angiogenesis are reviewed in details.

Key words: Anti-angiogenesis, Non-small cell lung cancer, VEGF, TKI

CLC Number:

R734.2

DAI Xin, ZHANG Daxin. Current status of anti-angiogenesis therapy for non-small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 472-476.

References

1 Rogosin S,Sandler AB.Beyond bevacizumab:antiangiogenic agents[J].Clin Lung Cancer,2012,13(5):326-333.
2 Jayson GC,Kerbel R,Ellis LM,et al.Antiangiogenic therapy in oncology:current status and future directions[J].Lancet,2016,388(10043):518-529.
3 Chen Y,Li X,Yang H,et al.Expression of basic fibroblast growth factor,CD31,and α-smooth muscle actin and esophageal cancer recurrence after definitive chemoradiation[J].Tumor Biol,2014,35(7):7275-7282.
4 Braghiroli MI,Sabbaga J,Hoff PM.Bevacizumab:overview of the literature[J].Expert Rev Anticancer Ther,2012,12(5):567-580.
5 Folkman J,Klagsbrun M.A family of angiogenic peptides[J].Nature,1987,329(6141):671-672.
6 Folkman J.Tumor angiogenesis:therapeutic implications[J].N Engl J Med,1971,285(21):1182-1186.
7 Alvarez RH,Kantarjian HM,Cortes JE.Biology of platelet-derived growth factor and its involvement in disease.[J].Mayo Clin Pro,2006,81(9):1241-1257.
8 Ferrara N,Gerber HP,LeCouter J.The biology of VEGF and its receptors[J].Nat Med,2003,9(6):669-676.
9 Ellis LM,Hicklin DJ.VEGF-targeted therapy:mechanisms of anti-tumour activity[J].Nat Rev Cancer,2008,8(8):579-591.
10 Abdollahi A,Hahnfeldt P,Maercker C,et al.Endostatin's antiangiogenic signaling network[J].Mol Cell,2004,13(5):649-663.
11 Ballas MS,Chachoua A.Rationale for targeting VEGF,FGF,and PDGF for the treatment of NSCLC[J].Oncotargets Ther,2011,4(1):43-58.
12 Ebos JML,Kerbel RS.Antiangiogenic therapy:impact on invasion,disease progression,and metastasis[J].Nat Rev Clin Oncol,2011,8(4):210-221.
13 Li J,Dai CH,Chen P,et al.Survival and prognostic factors in small cell lung cancer[J].Med Oncol,2010,27(1):73-81.
14 Niho S,Kunitoh H,Nokihara H,et al.Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.[J].Lung Cancer,2012,76(3):362.
15 Zhou C,Wu YL,Chen G,et al.BEYOND:A randomized,double-Blind,placebo-controlled,multicenter,phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer[J].J Clin Oncol,2015,33(19):2197.
16 Poole RM,Vaidya A.Ramucirumab:first global approval[J].Drugs,2014,74(9):1047-1058.
17 Garon EB,Ciuleanu TE,Arrieta O,et al.Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy(REVEL):a multicentre,double-blind,randomised phase 3 trial[J].Lancet,2014,384(9944):665-673.
18 Asahina H,Tamura Y,Nokihara H,et al.An open-label,phase 1 study evaluating safety,tolerability,and pharmacokinetics of linifanib(ABT-869)in Japanese patients with solid tumors[J].Cancer Chemoth Pharm,2012,69(6):1477-1486.
19 Horinouchi H,Yamamoto N,Nokihara H,et al.A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer(NSCLC)[J].Cancer Chemoth Pharm,2014,74(1):37-43.
20 Ramalingam SS,Shtivelband M,Soo RA,et al.Randomized Phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer[J].J Clin Oncol,2015,33(5):433-441.
21 Van C E,Tabernero J,Lakomy R,et al.Addition of aflibercept to fluorouracil,leucovorin,and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen[J].J Clin Oncol,2012,30(28):3499-3506.
22 Chen H,Modiano MR,Neal JW,et al.A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer[J].Brit J Cancer,2014,110(3):602-608.
23 Ramlau R,Gorbunova V,Ciuleanu TE,et al.Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer:A randomized,controlled phase III trial[J].J Clin Oncol,2012,30(29):3640-3647.
24 Bottsford-Miller JN,Coleman RL,Sood AK.Resistance and escape from antiangiogenesis therapy:clinical implications and future strategies[J].J Clin Oncol,2012,30(32):4026-4034.
25 Spigel DR,Greco FA,Shipley DL,et al.Randomized,double-blind,placebo-controlled,phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer[J].J Clin Oncol,2011,29(18):2582-2589.
26 Novello S,Scagliotti GV,Rosell R,et al.Novello S,Scagliotti G V,Rosell R,et al.Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer[J].Clin Lung Cancer,2009,101(9):1543-1548.
27 Morinaga Y,Suga Y,Ehara S,et al.Combination effect of AC‐7700,a novel combretastatin A-4 derivative,and cisplatin against murine and human tumors in vivo[J].Cancer Sci,2003,94(2):200-204.
28 Von PJ,Gorbounova V,Reck M,et al.DISRUPT:A randomised phase 2 trial of ombrabulin(AVE8062)plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer[J].Lung Cancer,2014,85(2):224-229.
29 McKeage MJ,Pawel JV,Reck M,et al.Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer[J].Brit J Cancer,2008,99(12):2006-2012.
30 Lara PN,Douillard JY,Nakagawa K,et al.Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan(ASA404)in advanced non-small-cell lung cancer[J].J Clin Oncol,2011,29(22):2965-2971.
31 Ma T,Fuld AD,Rigas JR,et al.A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients[J].Chemotherapy,2012,58(4):321-329.
32 Folkman J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J].Exp Cell Res,2006,312(5):594-607.
33 DeRose P,Thorpe PE,Gerber DE.Development of bavituximab,a vascular targeting agent with immune-modulating properties,for lung cancer treatment[J].Immunotherapy,2011,3(8):933-44.
34 Digumarti R,Bapsy PP,Suresh AV,et al.Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer[J].Lung Cancer,2014,86(2):231-236.
35 Damaraju VL,Kuzma M,Mowles D,et al.Interactions of multitargeted kinase inhibitors and nucleoside drugs:Achilles heel of combination therapy?[J].Mol Cancer Ther,2015,14(1):236-245.
36 Moserle L,Jiménez-Valerio G,Casanovas O.Antiangiogenic therapies:going beyond their limits[J].Cancer Discov,2014,4(1):31-41.

[1]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.
[2]	CAI Jing, HOU Yue. The expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 415-419.
[3]	LI Meiyan, CHEN Yongxue, HOU Junde. Effects of Leptin,VEGF and different anesthesia methods on prognosis of endometrial cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 426-431.
[4]	CUI Xiaoyan,TU Qing,GAN Jianhui. Comparison between nalbuphine and oxycodone applied for patient controlled analgesia on postoperative immunological factor levels in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 309-314.
[5]	LEI Junhua, XU Guanhua, ZENG Jiangzheng, HUANG Fen, HE Zhihui, LU Yanda. Research on JAK3/STAT3 mechanism of non-small cell lung cancer NCI-H1975 cells treated with cryptotanshinone combined with cisplatin [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 198-202.
[6]	ZHAI Keke, GAO Yuanyuan, FENG Xiao, XU Jingwen, GONG Yufang, MENG Qingwei. Analysis of first-line NSCLC chemotherapy in the phase Ⅳ patients with distant metastasis and first diagnosis after postoperative adjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 107-111.
[7]	DU Yesheng, HU Songliu, XU Xiangying. Study of oligodendrocyte metastasis in non-small cell lung cancer by stereotactic radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 154-158.
[8]	SUN Mingliang, XU Jianyu, XU Xiangying. Stereotactic radiotherapy for early stage of non - small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 53-56.
[9]	LIANG Yusi, TAN Yonggang, ZOU Huawei. Research progress on mechanism of low-dose chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 538-542.
[10]	HU Haifeng,FENG Xiemin,QIAO Jian,DUAN Wei,LIU Ningning,SUN Xiaodong. The expression and clinical significance of miR-345 in non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 117-122.
[11]	ZHANG Rui,WANG Zhiyu,WANG Shuai,ZHAO Hui. Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diagnosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 527-522.
[12]	REN Fenghai,WANG Dandan,WANG Junfeng,XU Hai,XU Shidong. Clinical comparative study between Uniportal and single port video-assisted thoracoscopic surgery for ⅠA stage non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 327-331.
[13]	YE Leiguang, YAN An, LIU Baogang. Relationship between Aurora-A mediated drug resistance and prognosis of patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 97-102.
[14]	CHEN Minghui, CHEN Xijie, WANG Yan. Research progress of CD44v6 in non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 172-175.
[15]	CHENG Long, ZHOU Jianguo, ZHOU Hang. Maintenance therapy with pemetrexed for advanced non-small cell lung cancer:A Meta-analysis of RCTs [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 28-35.

Current status of anti-angiogenesis therapy for non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments